Tremfya (guselkumab) / J&J 
Welcome,         Profile    Billing    Logout  
 11 Diseases   38 Trials   38 Trials   2495 News 


12345678910111213...3536»
  • ||||||||||  Tremfya (guselkumab) / J&J
    Preclinical, Journal:  A Novel human IL-23A Overexpressing Mouse Model of Systemic Lupus Erythematosus. (Pubmed Central) -  Feb 16, 2024   
    We have generated and characterized a novel genetic mouse model of SLE, providing proof-of-concept for the etiopathogenic role of hIL-23A. This new model has a normal lifespan and integrates several characteristics of the human disease's complexity and chronicity making it an attractive preclinical tool for studying IL23-dependent pathogenic mechanisms and assessing the efficacy of anti-hIL23A or modeled disease-related therapeutics.
  • ||||||||||  Risk of Clostridioides difficile infection in patients with inflammatory bowel disease (Poster exhibition) -  Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_2005;    
    For RHEUMA-Bio, the biologics included were infliximab, adalimumab, golimumab, certolizumab, ustekinumab, secukinumab, etanercept, abatacept, tocilizumab, rituximab, guselkumab and ixekizumab...Biologic therapy was not associated with a higher risk of CDI. In IBD patients on biologic therapy, the number of biologics received increased the risk of CDI.
  • ||||||||||  Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn (Poster exhibition) -  Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1637;    
    There was moderate certainty of evidence for combination of ADA and azathioprine (AZA) (RR 3.1, 95%CI [2.0-4.8]; risk difference [RD]: 40.1%), IFX+AZA (RR 2.5, 95%CI [1.7-3.8]; RD: 28.9%), ADA (RR 2.5, 95%CI [1.8-3.5]; RD:28.5%), and UST (RR 2.0 95%CI, [1.6-2.5]; RD: 19.2%) in induction of clinical remission compared to placebo...Conclusion On network meta-analysis, combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have examples of similarly important effect sizes, but are currently limited due to the imprecision of the limited evidence base at present and future research should target these therapies in study.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Development of a Crohn's disease molecular activity score to identify region-specific chronically inflamed and non-inflamed processes (Poster exhibition) -  Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1270;    
    P2/3
    Here, we provide a detailed molecular characterization of baseline ileal and colonic tissue from patients enrolled in the GALAXI Ph2b study of guselkumab in CD (NCT03466411) and explore the association of regional molecular profiles with endoscopic and histologic severity...Conclusion Application of the MAS to identify inflamed tissue enabled identification of key immune and inflammatory related processes across the ileum and colon that were associated with the IL-23 pathway, and baseline regional endoscopic and histologic severity. By identifying inflamed baseline samples, molecular changes associated with treatment can be more accurately defined in future analyses to better understand regional heterogeneity in CD.
  • ||||||||||  Review, Journal:  The Role of IL-23 Inhibitors in Crohn's Disease. (Pubmed Central) -  Jan 11, 2024   
    Risankizumab, mirikizumab, and guselkumab are specific IL-23p19 antagonists tested for the treatment of Crohn's disease (CD)...Trials with guselkumab and mirikizumab are currently ongoing, with promising preliminary efficacy and safety results. In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Journal:  Earlier clinical response predicts low rates of radiographic progression in biologic-na (Pubmed Central) -  Jan 9, 2024   
    In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD. In guselkumab-treated patients with active PsA, earlier improvement in joint symptoms significantly associated with lower RP rates through 2
  • ||||||||||  Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
    Journal:  Disease Characteristics, Pathogenesis, and Treatment Controversies of Axial Psoriatic Arthritis. (Pubmed Central) -  Jan 9, 2024   
    Recent post hoc analyses of clinical trial data with IL-23 inhibitors in PsA have raised the possibility of their efficacy in axPsA and need evaluation in future clinical trials. Moreover, there is a need for classification criteria for axPsA and better tools to assess therapeutic response.
  • ||||||||||  Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Tremfya (guselkumab) / J&J
    Real-world data on the effectiveness on IBD of anti-IL23 drugs prescribed for psoriasis indication (Poster exhibition) -  Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_945;    
    IL-23 inhibitors demonstrated a good safety profile in patients with IBD. Despite the limitations of the study with the need to publish further real-world data on a larger scale and with higher dosing of IL-23 inhibitors, the results obtained are promising as they, for the first time, provide real-life support for the clinical potential of these drugs as treatment for IBD in addition to psoriasis.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Guselkumab binding to CD64+ IL-23 (Poster exhibition) -  Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_682;    
    Guselkumab (GUS) and risankizumab (RZB) are monoclonal antibodies (mAbs) specifically directed against the IL-23p19 subunit. GUS binding to CD64 on IL-23